<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004482</url>
  </required_header>
  <id_info>
    <org_study_id>199/14209</org_study_id>
    <secondary_id>MAYOC-1479901</secondary_id>
    <secondary_id>MAYOC-1479900</secondary_id>
    <nct_id>NCT00004482</nct_id>
  </id_info>
  <brief_title>Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Assess the effect of immunosuppression with muromonab-CD3, cyclosporine,&#xD;
      methylprednisolone, and prednisone versus standard care in terms of death, heart&#xD;
      transplantation, or left ventricular assistive device placement in patients with giant cell&#xD;
      myocarditis.&#xD;
&#xD;
      II. Compare left ventricular ejection fraction prior to and after 4 weeks of treatment in&#xD;
      these arms.&#xD;
&#xD;
      III. Compare the degree of myocardial inflammatory infiltrate prior to and after 4 weeks of&#xD;
      treatment in these arms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:&#xD;
&#xD;
      This is a randomized, open label, multicenter study.&#xD;
&#xD;
      Patients are randomized to receive standard care with immunosuppression (arm I) or standard&#xD;
      care with or without immunosuppression (no muromonab-CD3 or cyclosporine)(arm II).&#xD;
&#xD;
      Arm I: Patients receive methylprednisolone IV once daily for 3 days and muromonab-CD3 IV once&#xD;
      daily for 10 days. Oral cyclosporine is administered twice daily and oral prednisone is&#xD;
      administered once daily for 1 year.&#xD;
&#xD;
      Arm II: Patients receive standard care with or without immunosuppression (no muromonab-CD3 or&#xD;
      cyclosporine).&#xD;
&#xD;
      Patients are followed for one year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>40</enrollment>
  <condition>Myocarditis</condition>
  <condition>Giant Cell Myocarditis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Muromonab-CD3</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Idiopathic giant cell myocarditis confirmed by endomyocardial biopsy&#xD;
&#xD;
        Heart failure and/or arrhythmia of less than 3 months duration&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Hepatic: AST/ALT no greater than 3 times upper limit of normal&#xD;
&#xD;
        Renal: Creatinine no greater than 2.5 mg/dL&#xD;
&#xD;
        Other: Not pregnant or nursing; Negative pregnancy test; Fertile patients must use&#xD;
        effective contraception; No clinical evidence of sepsis or active infection (e.g.&#xD;
        meningitis, osteomyelitis, etc.); No contraindication to immunosuppression; No allergy to&#xD;
        cyclosporine or muromonab-CD3; No other severe concurrent diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie T. Cooper, Jr.</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>September 8, 2010</last_update_submitted>
  <last_update_submitted_qc>September 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2010</last_update_posted>
  <keyword>cardiovascular and respiratory diseases</keyword>
  <keyword>giant cell myocarditis</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Muromonab-CD3</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

